Production (Stage)
PMV Pharmaceuticals, Inc.
PMVP
$0.97
$0.022.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.01M | 26.92M | 21.04M | 22.14M | 22.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.79M | 84.85M | 78.58M | 76.32M | 76.27M |
| Operating Income | -88.79M | -84.85M | -78.58M | -76.32M | -76.27M |
| Income Before Tax | -79.17M | -74.81M | -67.57M | -65.05M | -65.10M |
| Income Tax Expenses | -18.30M | -16.10M | -16.10M | -16.17M | 3.00K |
| Earnings from Continuing Operations | -60.88 | -58.71 | -51.47 | -48.88 | -65.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.88M | -58.71M | -51.47M | -48.88M | -65.10M |
| EBIT | -88.79M | -84.85M | -78.58M | -76.32M | -76.27M |
| EBITDA | -87.97M | -83.70M | -77.12M | -74.87M | -74.83M |
| EPS Basic | -1.18 | -1.14 | -1.00 | -0.97 | -1.32 |
| Normalized Basic EPS | -0.96 | -0.90 | -0.81 | -0.79 | -0.82 |
| EPS Diluted | -1.18 | -1.14 | -1.00 | -0.97 | -1.32 |
| Normalized Diluted EPS | -0.96 | -0.90 | -0.81 | -0.79 | -0.82 |
| Average Basic Shares Outstanding | 206.82M | 206.31M | 205.89M | 203.36M | 197.70M |
| Average Diluted Shares Outstanding | 206.82M | 206.31M | 205.89M | 203.36M | 197.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |